

Financial Tear Sheet

Corporate Profile

Accuray Incorporated is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Accuray does not assume a duty to update information on this website, except through the normal quarterly financial press releases and regulatory filings.

Stock Performance

ARAY (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$4.45
Change (%)	▼ 0.05 (1.11%)
Volume	247,893
52 Week Low	\$3.60
Market Cap	\$372,670,826
Rolling EPS	-0.36
PE Ratio	N/A
Shares Outstanding	83,746,253

Data as of Sep 25, 2017 4:00 p.m. ET



Press Releases

Sep 20, 2017 - 4:16 p.m.

Accuray Showcases CyberKnife® and Radixact™ Systems at ASTRO 2017

Aug 22, 2017 - 4:02 p.m.





Accuray Reports Fourth Quarter and Fiscal 2017 Financial Results

Aug 17, 2017 - 7:30 a.m.

Summit Cancer Center-Boise Treats Its First Cancer Patients Using the Accuray Radixact™ System

There are currently no events scheduled.

SEC Filings

Filing Date	Form	
Sep 11, 2017	CT ORDER	
Aug 31, 2017	4	
Aug 25, 2017	10-K	
Aug 22, 2017	8-K	

Corporate Governance

Joshua H. Levine	President and Chief Executive Officer
LIONEL HADJADJEB	SENIOR VICE PRESIDENT, CHIEF COMMERCIAL OFFICER
Kevin Waters	Senior Vice President, Chief Financial Officer
Darl S. Moreland	Senior Vice President, Regulatory, Quality and Compliance
Alaleh Nouri	Senior Vice President, General Counsel and Corporate Secretary
Andy Kirkpatrick	Senior Vice President, Global Operations and Corporate Development

Data provided by Nasdaq. Minimum 15 minutes delayed.

© 2007 - 2017 Accuray Incorporated. All Rights Reserved.